Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $6.34, $1.72 better than the analyst estimate of $4.62. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $981.08 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2026 revenue of $4.25-4.5 billion, versus the consensus of $4.453 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.